December 16, 2020 06:30 ET | Source: NeuBase Therapeutics, Inc.
In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts
Findings provide support for hypothesized mechanism of action of anti-gene, which is designed to not degrade the DMPK transcript
Data further validate the potential of the PATrOL platform to develop highly targeted therapies that increase, decrease or change causal protein function
NeuBase management to hold conference call and webcast today, December 16, at 8:00 a.m. EST
PITTSBURGH, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBases anti-gene approach to comprehensively treat the underlying cause of DM1.
Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients, said Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase. DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1.
Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, added, Using our proprietary PATrOL platform, we have designed a first-in-class anti-gene candidate that selectively binds mutant DMPK mRNA and opens its hairpin secondary structure, as opposed to a mechanism of action that explicitly degrades the mutant and wild-type transcripts indiscriminately, making it a unique option for the treatment of DM1. These in vitro and in vivo data both support our hypothesized mechanism of action and demonstrate rapid and broad resolution of the mis-splicing that is the primary cause of DM1.
This is the second set of positive data that weve announced in 2020 for our PATrOL-enabled therapies, which we believe serves as proof of concept that further validates our technologic foundation. With a single unified platform, we believe we can increase, decrease or change protein function of potentially any nucleic acid target, unique among genetic medicine approaches. We are excited by the progress we have made and look forward to providing additional updates on our platform and pipeline of programs at an R&D day in the first half of 2021.
In vitro data highlights in DM1 patient-derived fibroblasts:
In vivo data highlights in the HSALR transgenic mouse model of DM1 that expresses high levels of mutant CUG-repeat-containing mRNA (HSA) in skeletal muscle:
DM1 is a rare, autosomal dominant repeat expansion disorder characterized by progressive muscle wasting and weakness. It also affects the central nervous system (CNS) and heart. DM1 is caused by CTG nucleic acid repeats in the DMPK gene that produce a hairpin structure in the transcribed DMPK mRNA. The hairpin structure sequesters critical splice regulators and results in the mis-splicing of multiple gene transcripts. Furthermore, the binding of splice regulators traps the mutant DMPK mRNA in the nucleus, resulting in DMPK protein haploinsufficiency, or half the level of protein that is needed for normal function, which is thought to exacerbate the CNS and cardiac symptoms that are characteristic of DM1 (as knock-out mice for Dmpk show both severe cardiac conduction defects as well as issues with neuronal cytoskeletal remodeling manifesting in aberrant long-term potentiation). The prevalence of DM1 is >5/100,000 in the general population. There are currently no approved treatments for DM1.
Conference Call and Webcast Details
NeuBase Therapeutics, Inc. will discuss these data during a webcasted conference call with slides today, December 16, 2020, at 8:00 a.m. EST. To access the webcast, please click here. An archived recording of this presentation will be available following the call through the IR Calendar page on the Investors section of the Companys website, http://www.neubasetherapeutics.com.
About NeuBase Therapeutics, Inc. NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase's designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit http://www.neubasetherapeutics.com.
Use of Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the potential significance and implications of the Companys positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com OP: (617) 430-7576
NeuBase Media Contact: Cait Williamson, Ph.D. LifeSci Communications cait@lifescicomms.com OP: (646) 751-4366
Read more from the original source:
NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 -...
- Cardiac MR PET CT Program - Massachusetts General Hospital, Boston, MA - April 12th, 2018 [April 12th, 2018]
- The History, Physical Examination, and Cardiac ... - April 21st, 2018 [April 21st, 2018]
- Dor procedure - Wikipedia - April 26th, 2018 [April 26th, 2018]
- Cardiac Remodeling and Its Significance - Verywell - May 13th, 2018 [May 13th, 2018]
- AndrewMcCulloch - Cardiac Mechanics Research Group - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardiac Nursing Events ... - June 3rd, 2018 [June 3rd, 2018]
- Cardiac MR PET CT Program - Massachusetts General Hospital ... - June 5th, 2018 [June 5th, 2018]
- Cardiac resynchronization therapy - Wikipedia - June 23rd, 2018 [June 23rd, 2018]
- Cardiac Remodeling and Its Significance - verywellhealth.com - October 5th, 2018 [October 5th, 2018]
- Ventricular remodeling - Wikipedia - December 21st, 2018 [December 21st, 2018]
- The Significance of Cardiac Remodeling - verywellhealth.com - December 21st, 2018 [December 21st, 2018]
- Ventricular hypertrophy - Wikipedia - December 26th, 2018 [December 26th, 2018]
- Cardiac remodelingconcepts and clinical implications: a ... - April 3rd, 2019 [April 3rd, 2019]
- Emerging roles of proteoglycans in cardiac remodeling ... - May 23rd, 2019 [May 23rd, 2019]
- Antibody could fine-tune recovery from heart attack - Futurity: Research News - September 27th, 2019 [September 27th, 2019]
- What are the respiratory effects of e-cigarettes? - The BMJ - October 3rd, 2019 [October 3rd, 2019]
- AI Pinpoints Genes Associated With Heart Failure - Forbes - October 3rd, 2019 [October 3rd, 2019]
- PH Common in Myeloproliferative Neoplasms, Linked to Diastolic Dysfunction - The Cardiology Advisor - October 26th, 2019 [October 26th, 2019]
- Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling - DocWire... - November 6th, 2019 [November 6th, 2019]
- Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019 - GlobeNewswire - November 15th, 2019 [November 15th, 2019]
- Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights - P&T Community - November 15th, 2019 [November 15th, 2019]
- Ibrutinib and Hypertension in CLL: What Are the Risks? - Cancer Therapy Advisor - November 23rd, 2019 [November 23rd, 2019]
- What's being done to close the research gap when it comes to men's and women's cardiac health - The Loop - November 23rd, 2019 [November 23rd, 2019]
- Heart Ventricle Remodeling - an overview | ScienceDirect ... - November 26th, 2019 [November 26th, 2019]
- Denise Merkl, 1949-2019 The Times-Independent - The Times-Independent - December 16th, 2019 [December 16th, 2019]
- Is There a Future for CAR T-Cell Therapy in Heart Failure? - AJMC.com Managed Markets Network - December 16th, 2019 [December 16th, 2019]
- $13 Million Grant to Probe the Genome of Heart Cells - PRNewswire - December 18th, 2019 [December 18th, 2019]
- TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure - BioSpace - December 18th, 2019 [December 18th, 2019]
- News - Michigan Lawmaker to Offer CON Reforms - The Heartland Institute - December 28th, 2019 [December 28th, 2019]
- Personalized Medicine for AFib: How Electric Activity in the Heart Can Predict Individual Progression of Atrial Fibrillation - DocWire News - December 28th, 2019 [December 28th, 2019]
- Cardiac Restoration Systems Market Drives, Emerging Trends, Key Value And Forecast 2025 - Industry Mirror - December 31st, 2019 [December 31st, 2019]
- New Living Machines Are Created in the Lab - Tufts Now - January 16th, 2020 [January 16th, 2020]
- Man thinks sepsis was a cold and loses his leg on his 40th birthday - Information-Analytic Agency NEWS.am - January 25th, 2020 [January 25th, 2020]
- Could Colchicine Be the New Aspirin? - Medscape - January 28th, 2020 [January 28th, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - Renal and Urology News - January 28th, 2020 [January 28th, 2020]
- Link between chronic kidney disease and heart failure is identified in patients - UAB News - February 9th, 2020 [February 9th, 2020]
- Advancing an oral drug for pulmonary arterial hypertension - Penn: Office of University Communications - February 15th, 2020 [February 15th, 2020]
- MR Improves in Half of Low-Flow/Low-Gradient AS Patients Undergoing TAVR - TCTMD - February 15th, 2020 [February 15th, 2020]
- Varied Nightly Bedtime, Sleep Duration Linked to CVD Risk - Medscape - March 4th, 2020 [March 4th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Business Wire - March 4th, 2020 [March 4th, 2020]
- Slump in Production of Absorbable Heart Stent Amidst Covid-19 Outbreak to Diminish Prospects of Sales - Jewish Life News - May 7th, 2020 [May 7th, 2020]
- Cardiol Therapeutics files patent to use CBD therapies for patients with coronavirus - Proactive Investors USA & Canada - May 7th, 2020 [May 7th, 2020]
- The Effector Cells and Cellular Mediators of Immune System Involved in Cardiac Inflammation and Fibrosis after Myocardial Infarction - DocWire News - May 7th, 2020 [May 7th, 2020]
- Cardiac Restoration Systems Market Detailed Analysis and Forecast 2018-2028 3w Market News Reports - 3rd Watch News - May 16th, 2020 [May 16th, 2020]
- LV Mass Regression After TAVR Linked to Better Long-term Outcomes - TCTMD - May 16th, 2020 [May 16th, 2020]
- Hypoxic Training Equipment Industry to 2026; Featuring Profiles of Biomedtech Australia, Go2 Altitude, Gooxygen, Higher Peak, and More - GlobeNewswire - May 16th, 2020 [May 16th, 2020]
- Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix - May 16th, 2020 [May 16th, 2020]
- $125619 awarded in spring Community Needs Grants - The MidWeek - May 20th, 2020 [May 20th, 2020]
- Absorbable Cardiac Stent Market 2020-2026 Growth Trends, Leading Players, Competitive Strategies and 2026 Future Prospect - Cole of Duty - June 15th, 2020 [June 15th, 2020]
- The Protective Effects of Liguzinediol on Congestive Heart Failure Induced by Myocardial Infarction and Its Relative Mechanism - DocWire News - June 19th, 2020 [June 19th, 2020]
- ABSORBABLE HEART STENT Sales Market 2020-2026: Analysis by Growth Factors, Key Trends and Competitive Strategies - Cole of Duty - June 19th, 2020 [June 19th, 2020]
- Absorbable Heart Stent Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:... - June 19th, 2020 [June 19th, 2020]
- Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease - Science Advances - June 19th, 2020 [June 19th, 2020]
- Worldwide Comprehensive Review of Absorbable Cardiac Stent Market Trends and Its Development - 3rd Watch News - June 22nd, 2020 [June 22nd, 2020]
- Absorbable Heart Stent Market In-deep Analysis And Experts Review Report 2020-2026 - Cole of Duty - June 22nd, 2020 [June 22nd, 2020]
- Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No... - July 1st, 2020 [July 1st, 2020]
- Cardiac Restoration Systems Market Analysis with Key Players, Applications, Trends and Forecast to 2027 - Jewish Life News - July 1st, 2020 [July 1st, 2020]
- Women Thrive on Baroreflex Activation for Heart Failure - Medscape - July 1st, 2020 [July 1st, 2020]
- Meet Inspiring young Doctor from Gallipolis, Ohio USA: Dr Wilton Triggs II - International Business Times, Singapore Edition - August 19th, 2020 [August 19th, 2020]
- Absorbable Heart Stent Market Research 2020-Competitive Insights: Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 19th, 2020 [August 19th, 2020]
- Novel mechanism connects SPEG, RyR2 and atrial fibrillation - Baylor College of Medicine News - August 19th, 2020 [August 19th, 2020]
- Comprehensive Analysis On Absorbable Heart Stent Market Insights Abbott Laboratories, Biotronik, Arterial Remodeling Technologies, Amaranth Medica -... - August 28th, 2020 [August 28th, 2020]
- Lincolnton man wrestles with COVID and wins | News - Lincoln Times-News - August 28th, 2020 [August 28th, 2020]
- Impact of sex on timing and clinical outcome of septal myectomy for obstructive hypertrophic cardiomyopathy - DocWire News - August 28th, 2020 [August 28th, 2020]
- Adverse Remodeling in Atrial Fibrillation Following Isolated Aortic Valve Replacement Surgery - DocWire News - August 28th, 2020 [August 28th, 2020]
- EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice - DocWire News - August 28th, 2020 [August 28th, 2020]
- Business Notebook: Several 'pro-business' laws now in effect; SEMO joins forces with Codefi - Southeast Missourian - August 31st, 2020 [August 31st, 2020]
- Global Absorbable Heart Stent Market Covid-19 Impact Analysis, Leading Player, Application, New Product Developments and 2024 Forecast - The Daily... - August 31st, 2020 [August 31st, 2020]
- Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week - DocWire News - August 31st, 2020 [August 31st, 2020]
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiation - Science... - September 15th, 2020 [September 15th, 2020]
- 3D curvature-instructed endothelial flow response and tissue vascularization - Science Advances - September 19th, 2020 [September 19th, 2020]
- FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity - Science Advances - September 19th, 2020 [September 19th, 2020]
- Denervation Therapy Ventures Where Drugs Have Failed: HFpEF - Medscape - October 14th, 2020 [October 14th, 2020]
- Comprehensive Report on Absorbable Heart Stent Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Impact Of Covid 19 Analysis... - November 26th, 2020 [November 26th, 2020]
- Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study... - November 26th, 2020 [November 26th, 2020]
- Elite Soccer Players Have Big Hearts and That's Okay - Medscape - December 20th, 2020 [December 20th, 2020]
- A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis - DocWire News - January 20th, 2021 [January 20th, 2021]
- Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System - Business Wire - January 20th, 2021 [January 20th, 2021]
- Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis - DocWire... - January 20th, 2021 [January 20th, 2021]
- Global Absorbable Heart Stent Market Development Factors 2020 Overview by Regional Analysis, Industry Size, Business Share, Growth Rate Forecast to... - January 31st, 2021 [January 31st, 2021]